pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Taiho Pharma Canada
Taiho Pharma Netherlands B.V.
Taiho Pharma Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Sol
2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA HQ
2017 Founded
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
- Founded
- 2017
- Employees
- 13
- Programs
- 16
- Drugs
- 30
- Patents
- 0
TAS6417-302
Phase 3 · small molecule · Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
TAS6417-302 for Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations is a Phase 3 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code TAS6417-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Taiho Pharma Netherlands B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
- Status
- active
- Trials
- 1